The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Commentary|Articles|June 12, 2026
Targeted Therapies, Frontline Combos Headline Key Lung Cancer Data to Emerge From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Tracy Ann Politowicz, Chris Ryan
Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
As data emerged across the non–small cell lung cancer (NSCLC) space at the 2026 ASCO Annual Meeting, experts from the field outlined some of the most crucial findings that could impact future clinical approaches.
Related to this article
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.
Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.
Advertisement
Advertisement